These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15313413)

  • 1. Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders.
    Rouaux C; Loeffler JP; Boutillier AL
    Biochem Pharmacol; 2004 Sep; 68(6):1157-64. PubMed ID: 15313413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.
    Anne-Laurence B; Caroline R; Irina P; Jean-Philippe L
    Subcell Biochem; 2007; 41():263-93. PubMed ID: 17484132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
    Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
    Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning acetylation levels with HAT activators: therapeutic strategy in neurodegenerative diseases.
    Selvi BR; Cassel JC; Kundu TK; Boutillier AL
    Biochim Biophys Acta; 2010; 1799(10-12):840-53. PubMed ID: 20833281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration.
    Rouaux C; Jokic N; Mbebi C; Boutillier S; Loeffler JP; Boutillier AL
    EMBO J; 2003 Dec; 22(24):6537-49. PubMed ID: 14657026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.
    Langley B; Gensert JM; Beal MF; Ratan RR
    Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):41-50. PubMed ID: 15723612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease.
    Janknecht R
    Histol Histopathol; 2002 Apr; 17(2):657-68. PubMed ID: 11962765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
    Ganai SA; Banday S; Farooq Z; Altaf M
    Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To learn better, keep the HAT on.
    Martin KC; Sun YE
    Neuron; 2004 Jun; 42(6):879-81. PubMed ID: 15207231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration.
    Alarcón JM; Malleret G; Touzani K; Vronskaya S; Ishii S; Kandel ER; Barco A
    Neuron; 2004 Jun; 42(6):947-59. PubMed ID: 15207239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation.
    Vecsey CG; Hawk JD; Lattal KM; Stein JM; Fabian SA; Attner MA; Cabrera SM; McDonough CB; Brindle PK; Abel T; Wood MA
    J Neurosci; 2007 Jun; 27(23):6128-40. PubMed ID: 17553985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors reduce polyglutamine toxicity.
    McCampbell A; Taye AA; Whitty L; Penney E; Steffan JS; Fischbeck KH
    Proc Natl Acad Sci U S A; 2001 Dec; 98(26):15179-84. PubMed ID: 11742087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.
    Kazantsev AG; Thompson LM
    Nat Rev Drug Discov; 2008 Oct; 7(10):854-68. PubMed ID: 18827828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors improve learning consolidation in young and in KA-induced-neurodegeneration and SAMP-8-mutant mice.
    Fontán-Lozano A; Romero-Granados R; Troncoso J; Múnera A; Delgado-García JM; Carrión AM
    Mol Cell Neurosci; 2008 Oct; 39(2):193-201. PubMed ID: 18638560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein.
    Taylor JP; Taye AA; Campbell C; Kazemi-Esfarjani P; Fischbeck KH; Min KT
    Genes Dev; 2003 Jun; 17(12):1463-8. PubMed ID: 12815067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CBP and histone deacetylase inhibition enhance the transactivation potential of the HOXB7 homeodomain-containing protein.
    Chariot A; van Lint C; Chapelier M; Gielen J; Merville MP; Bours V
    Oncogene; 1999 Jul; 18(27):4007-14. PubMed ID: 10435624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CBP, a transcriptional coactivator and acetyltransferase.
    McManus KJ; Hendzel MJ
    Biochem Cell Biol; 2001; 79(3):253-66. PubMed ID: 11467739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.
    Gray SG; Dangond F
    Epigenetics; 2006; 1(2):67-75. PubMed ID: 17998807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
    Konsoula Z; Barile FA
    J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.